AMPLITUDE SURGICAL SAS(EPA:AMPLI) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to AMPLI. AMPLI was compared to 55 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of AMPLI while its profitability can be described as average. AMPLI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AMPLI was profitable.

AMPLI had a positive operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: AMPLI reported negative net income in multiple years.

AMPLI had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 0.55%, AMPLI is in line with its industry, outperforming 49.09% of the companies in the same industry.

The Return On Equity of AMPLI (1.59%) is comparable to the rest of the industry.

Looking at the Return On Invested Capital, with a value of 3.14%, AMPLI is in line with its industry, outperforming 50.91% of the companies in the same industry.

The Average Return On Invested Capital over the past 3 years for AMPLI is significantly below the industry average of 8.28%.

The last Return On Invested Capital (3.14%) for AMPLI is above the 3 year average (2.90%), which is a sign of increasing profitability.

		Industry Rank	Sector Rank
ROA	0.55%
ROE	1.59%
ROIC	3.14%

ROA(3y)4.54%

ROA(5y)0.64%

ROE(3y)11.48%

ROE(5y)-1.81%

ROIC(3y)2.9%

ROIC(5y)N/A

1.3 Margins

AMPLI's Profit Margin of 1.44% is in line compared to the rest of the industry. AMPLI outperforms 49.09% of its industry peers.

Looking at the Operating Margin, with a value of 9.43%, AMPLI is in the better half of the industry, outperforming 61.82% of the companies in the same industry.

AMPLI has a Gross Margin of 79.36%. This is amongst the best in the industry. AMPLI outperforms 89.09% of its industry peers.

AMPLI's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	9.43%
PM (TTM)	1.44%
GM	79.36%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.67%

GM growth 5Y9.09%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AMPLI is destroying value.

AMPLI has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, AMPLI has more shares outstanding

The debt/assets ratio for AMPLI is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.98, we must say that AMPLI is in the distress zone and has some risk of bankruptcy.

AMPLI has a Altman-Z score (0.98) which is in line with its industry peers.

A Debt/Equity ratio of 1.08 is on the high side and indicates that AMPLI has dependencies on debt financing.

AMPLI has a worse Debt to Equity ratio (1.08) than 80.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.08
Debt/FCF	N/A
Altman-Z	0.98

ROIC/WACC0.51

WACC6.22%

2.3 Liquidity

A Current Ratio of 2.02 indicates that AMPLI has no problem at all paying its short term obligations.

The Current ratio of AMPLI (2.02) is better than 61.82% of its industry peers.

A Quick Ratio of 1.09 indicates that AMPLI should not have too much problems paying its short term obligations.

AMPLI has a Quick ratio (1.09) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.02
Quick Ratio	1.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AMPLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -96.07%.

Looking at the last year, AMPLI shows a small growth in Revenue. The Revenue has grown by 5.81% in the last year.

Measured over the past years, AMPLI shows a small growth in Revenue. The Revenue has been growing by 0.67% on average per year.

EPS 1Y (TTM)-96.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-96.06%

Revenue 1Y (TTM)5.81%

Revenue growth 3Y8.63%

Revenue growth 5Y0.67%

Sales Q2Q%3.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 113.33, the valuation of AMPLI can be described as expensive.

The rest of the industry has a similar Price/Earnings ratio as AMPLI.

When comparing the Price/Earnings ratio of AMPLI to the average of the S&P500 Index (29.35), we can say AMPLI is valued expensively.

		Industry Rank	Sector Rank
PE	113.33
Fwd PE	N/A

4.2 Price Multiples

AMPLI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMPLI is cheaper than 87.27% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	11.78

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AMPLI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AMPLITUDE SURGICAL SAS

EPA:AMPLI (3/7/2025, 7:00:00 PM)

3.4

+0.04 (+1.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)02-20 2025-02-20

Earnings (Next)04-17 2025-04-17

Inst Owners0.11%

Inst Owner ChangeN/A

Ins Owners0.26%

Ins Owner ChangeN/A

Market Cap163.27M

Analysts40

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	113.33
Fwd PE	N/A
P/S	1.54
P/FCF	N/A
P/OCF	40.38
P/B	1.7
P/tB	N/A
EV/EBITDA	11.78

EPS(TTM)0.03

EY0.88%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.31

FCFYN/A

OCF(TTM)0.08

OCFY2.48%

SpS2.21

BVpS2

TBVpS-0.84

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	0.55%
ROE	1.59%
ROCE	4.3%
ROIC	3.14%
ROICexc	3.59%
ROICexgc	10.71%
OM	9.43%
PM (TTM)	1.44%
GM	79.36%
FCFM	N/A

ROA(3y)4.54%

ROA(5y)0.64%

ROE(3y)11.48%

ROE(5y)-1.81%

ROIC(3y)2.9%

ROIC(5y)N/A

ROICexc(3y)3.33%

ROICexc(5y)N/A

ROICexgc(3y)9.78%

ROICexgc(5y)N/A

ROCE(3y)3.96%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.67%

GM growth 5Y9.09%

F-Score6

Asset Turnover0.38

Health

		Industry Rank	Sector Rank
Debt/Equity	1.08
Debt/FCF	N/A
Debt/EBITDA	4.88
Cap/Depr	168.94%
Cap/Sales	17.86%
Interest Coverage	250
Cash Conversion	19.06%
Profit Quality	N/A
Current Ratio	2.02
Quick Ratio	1.09
Altman-Z	0.98

F-Score6

WACC6.22%

ROIC/WACC0.51

Cap/Depr(3y)129.83%

Cap/Depr(5y)100.73%

Cap/Sales(3y)17.03%

Cap/Sales(5y)14.71%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-96.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-96.06%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)5.81%

Revenue growth 3Y8.63%

Revenue growth 5Y0.67%

Sales Q2Q%3.59%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y23.33%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-31.81%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-50.06%

OCF growth 3Y19.93%

OCF growth 5Y-13.28%

AMPLITUDE SURGICAL SAS (AMPLI.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens